Mind Medicine (MindMed) Inc. (MNMD), one of the sector’s largest clinical stage biopharmaceutical companies focused on developing novel products to treat brain health disorders, reported its financial results for the full-year ended December 31, 2021 earlier this week.
Like most companies in the space, it’s been relatively difficult to report meaningful revenue.
And MindMed, despite having its first-mover advantage after going public in 2019, is no exception to the rule.
The net and comprehensive loss for the year ended December 31, 2021 was $92.3 million, compared to $33.7 million for the year ended 2020. That means the company earned 173% less this year compared to last year.
But before anyone jumps to conclusions, we have a lot more to unpack.
As our very own Adam Tubero explains, reported net income isn’t the only headscratcher for investors. Tune in to the latest video breakdown above to learn more about MindMed’s pipeline, its latest cash burn and balance results, and how investors reacted to the news.